Autophagy modulation as a target for anticancer drug discovery

被引:0
|
作者
Xin Li
Huai-long Xu
Yong-xi Liu
Na An
Si Zhao
Jin-ku Bao
机构
[1] School of Life Sciences & State Laboratory of Bio-resources and Eco-environment,
[2] Ministry of Education,undefined
[3] Sichuan University,undefined
来源
关键词
autophagy; cancer; apoptosis; anti-cancer drug; microRNA;
D O I
暂无
中图分类号
学科分类号
摘要
Autophagy, an evolutionarily conserved catabolic process involving the engulfment and degradation of non-essential or abnormal cellular organelles and proteins, is crucial for homeostatic maintenance in living cells. This highly regulated, multi-step process has been implicated in diverse diseases including cancer. Autophagy can function as either a promoter or a suppressor of cancer, which makes it a promising and challenging therapeutic target. Herein, we overview the regulatory mechanisms and dual roles of autophagy in cancer. We also describe some of the representative agents that exert their anticancer effects by regulating autophagy. Additionally, some emerging strategies aimed at modulating autophagy are discussed as having the potential for future anticancer drug discovery. In summary, these findings will provide valuable information to better utilize autophagy in the future development of anticancer therapeutics that meet clinical requirements.
引用
收藏
页码:612 / 624
页数:12
相关论文
共 50 条
  • [41] Thiazole in the targeted anticancer drug discovery
    Ayati, Adileh
    Emami, Saeed
    Moghimi, Setareh
    Foroumadi, Alireza
    [J]. FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1929 - 1952
  • [42] Thymidylate synthase as a molecular target for drug discovery using the National Cancer Institute's Anticancer Drug Screen
    Parr, AL
    Myers, TG
    Holbeck, SL
    Loh, YLJ
    Allegra, CJ
    [J]. ANTI-CANCER DRUGS, 2001, 12 (07) : 569 - 574
  • [43] The anticancer drug imatinib induces cellular autophagy
    A Ertmer
    V Huber
    S Gilch
    T Yoshimori
    V Erfle
    J Duyster
    H-P Elsässer
    H M Schätzl
    [J]. Leukemia, 2007, 21 : 936 - 942
  • [44] The anticancer drug imatinib induces cellular autophagy
    Ertmer, A.
    Huber, V.
    Gilch, S.
    Yoshimori, T.
    Erfle, V.
    Duyster, J.
    Elsaesser, H-P
    Schaetzl, H. M.
    [J]. LEUKEMIA, 2007, 21 (05) : 936 - 942
  • [45] Modulation of Epigenetic Targets for Anticancer Therapy: Clinicopathological Relevance, Structural Data and Drug Discovery Perspectives
    Andreoli, Federico
    Barbosa, Armenio Jorge Moura
    Parenti, Marco Daniele
    Del Rio, Alberto
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (04) : 578 - 613
  • [46] The molecular co-chaperone HDJ2 as a target for anticancer drug discovery.
    Bagatell, R
    Chen, D
    Whitesell, L
    [J]. CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3682S - 3683S
  • [47] Target class drug discovery
    Kimberly D Barnash
    Lindsey I James
    Stephen V Frye
    [J]. Nature Chemical Biology, 2017, 13 : 1053 - 1056
  • [48] Proteomics for drug target discovery
    Gottfries, J
    Sjögren, M
    Holmberg, B
    Rosengren, L
    Davidsson, P
    Blennow, K
    [J]. CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2004, 73 (01) : 47 - 53
  • [49] The adipocyte as a drug discovery target
    Nawrocki, AR
    Scherer, PE
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (18) : 1219 - 1230
  • [50] Genomics in target and drug discovery
    van Duin, M
    Woolson, H
    Mallinson, D
    Black, D
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 429 - 432